Filoviral immune evasion mechanisms

Viruses

Volumn 3, Issue 9, 2011, Pages 1634-1649

  Ramanan, Parameshwaran ^a   Shabman, Reed S ^b   Brown, Craig S ^a   Amarasinghe, Gaya K ^a   Basler, Christopher F ^b   Leung, Daisy W ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Ebolavirus; IFN antagonist; Innate immune evasion; Marburgvirus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; I KAPPA B KINASE EPSILON; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; JANUS KINASE; KARYOPHERIN ALPHA; PHOSPHOTRANSFERASE; RETINOIC ACID INDUCIBLE PROTEIN I; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; TANK BINDING KINASE 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN 24; VIRUS PROTEIN 35; VIRUS PROTEIN 40; VIRUS RNA;

ADAPTIVE IMMUNITY; ARTICLE; DISEASE ASSOCIATION; DOWN REGULATION; EBOLA VIRUS; ENZYME INHIBITION; FILOVIRUS; FILOVIRUS INFECTION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOREACTIVITY; INNATE IMMUNITY; INTERFERON PRODUCTION; MARBURG VIRUS; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA INTERFERENCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS IMMUNITY; VIRUS REPLICATION;

EBOLAVIRUS; IFN ANTAGONIST; INNATE IMMUNE EVASION; MARBURGVIRUS;

ADAPTIVE IMMUNITY; ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERON TYPE I; MARBURG VIRUS DISEASE; MARBURGVIRUS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRUS REPLICATION;

EBOLA VIRUS; FILOVIRIDAE; MARBURGVIRUS;

EID: 80053309590     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3091634     Document Type: Article

References (53)

1. Groseth, A.; Stroher, U.; Theriault, S.; Feldmann, H. Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. Virus Res. 2002, 87, 155-163.
2. Jahrling, P.B.; Geisbert, T.W.; Dalgard, D.W.; Johnson, E.D.; Ksiazek, T.G.; Hall, W.C.; Peters, C.J. Preliminary report: Isolation of Ebola virus from monkeys imported to USA. Lancet 1990, 335, 502-505.
3. Barrette, R.W.; Metwally, S.A.; Rowland, J.M.; Xu, L.; Zaki, S.R.; Nichol, S.T.; Rollin, P.E.; Towner, J.S.; Shieh, W.J.; Batten, B. et al. Discovery of swine as a host for the Reston ebolavirus. Science 2009, 325, 204-206.
4. Leroy, E.M.; Kumulungui, B.; Pourrut, X.; Rouquet, P.; Hassanin, A.; Yaba, P.; Delicat, A.; Paweska, J.T.; Gonzalez, J.P.; Swanepoel, R. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438, 575-576.
5. Towner, J.S.; Pourrut, X.; Albarino, C.G.; Nkogue, C.N.; Bird, B.H.; Grard, G.; Ksiazek, T.G.; Gonzalez, J.P.; Nichol, S.T.; Leroy, E.M. Marburg virus infection detected in a common African bat. PLoS One 2007, 2, e764.
6. Towner, J.S.; Amman, B.R.; Sealy, T.K.; Carroll, S.A.; Comer, J.A.; Kemp, A.; Swanepoel, R.; Paddock, C.D.; Balinandi, S.; Khristova, M.L. et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 2009, 5, e1000536.
7. Bray, M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 2001, 82, 1365-1373.
8. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet 2011, 377, 849-862.
9. Takeuchi, O.; Akira, S. Innate immunity to virus infection. Immunol. Rev. 2009, 227, 75-86.
10. Yoneyama, M.; Fujita, T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev. 2009, 227, 54-65.
11. Katze, M.G.; He, Y.; Gale, M., Jr. Viruses and interferon: A fight for supremacy. Nat. Rev. Immunol. 2002, 2, 675-687.
12. Hartman, A.L.; Ling, L.; Nichol, S.T.; Hibberd, M.L. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 2008, 82, 5348-5358.
13. Kash, J.C.; Muhlberger, E.; Carter, V.; Grosch, M.; Perwitasari, O.; Proll, S.C.; Thomas, M.J.; Weber, F.; Klenk, H.D.; Katze, M.G. Global suppression of the host antiviral response by Ebolaand Marburgviruses: Increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 2006, 80, 3009-3020.
14. Mehedi, M.; Falzarano, D.; Seebach, J.; Hu, X.; Carpenter, M.S.; Schnittler, H.J.; Feldmann, H. A new ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 2011, 85, 5406-5414.
15. Basler, C.F.; Mikulasova, A.; Martinez-Sobrido, L.; Paragas, J.; Muhlberger, E.; Bray, M.; Klenk, H.D.; Palese, P.; Garcia-Sastre, A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77, 7945-7956.
16. Basler, C.F.; Wang, X.; Muhlberger, E.; Volchkov, V.; Paragas, J.; Klenk, H.D.; Garcia-Sastre, A.; Palese, P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 12289-12294.
17. Cardenas, W.B.; Loo, Y.M.; Gale, M., Jr.; Hartman, A.L.; Kimberlin, C.R.; Martinez-Sobrido, L.; Saphire, E.O.; Basler, C.F. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80, 5168-5178.
18. Hartman, A.L.; Towner, J.S.; Nichol, S.T. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328, 177-184.
19. Hartman, A.L.; Dover, J.E.; Towner, J.S.; Nichol, S.T. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 2006, 80, 6430-6440.
20. Leung, D.W.; Ginder, N.D.; Fulton, D.B.; Nix, J.; Basler, C.F.; Honzatko, R.B.; Amarasinghe, G.K. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 411-416.
21. Leung, D.W.; Prins, K.C.; Borek, D.M.; Farahbakhsh, M.; Tufariello, J.M.; Ramanan, P.; Nix, J.C.; Helgeson, L.A.; Otwinowski, Z.; Honzatko, R.B. et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 2010, 17, 165-172.
22. Prins, K.C.; Delpeut, S.; Leung, D.W.; Reynard, O.; Volchkova, V.A.; Reid, S.P.; Ramanan, P.; Cardenas, W.B.; Amarasinghe, G.K.; Volchkov, V.E. et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010, 84, 3004-3015.
23. Reid, S.P.; Cardenas, W.B.; Basler, C.F. Homo-oligomerization facilitates the interferonantagonist activity of the ebolavirus VP35 protein. Virology 2005, 341, 179-189.
24. Prins, K.C.; Cardenas, W.B.; Basler, C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 2009, 83, 3069-3077.
25. Chang, T.H.; Kubota, T.; Matsuoka, M.; Jones, S.; Bradfute, S.B.; Bray, M.; Ozato, K. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009, 5, e1000493.
26. Feng, Z.; Cerveny, M.; Yan, Z.; He, B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 2007, 81, 182-192.
27. Schumann, M.; Gantke, T.; Muhlberger, E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 2009, 83, 8993-8997.
28. Haasnoot, J.; de Vries, W.; Geutjes, E.J.; Prins, M.; de Haan, P.; Berkhout, B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 2007, 3, e86.
29. Fabozzi, G.; Nabel, C.S.; Dolan, M.A.; Sullivan, N.J. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 2011, 85, 2512-2523.
30. Kimberlin, C.R.; Bornholdt, Z.A.; Li, S.; Woods, V.L., Jr.; MacRae, I.J.; Saphire, E.O. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 314-319.
31. Leung, D.W.; Shabman, R.S.; Farahbakhsh, M.; Prins, K.C.; Borek, D.M.; Wang, T.; Muhlberger, E.; Basler, C.F.; Amarasinghe, G.K. Structural and Functional Characterization of Reston Ebola Virus VP35 Interferon Inhibitory Domain. J. Mol. Biol. 2010, 399, 347-357.
32. Reid, S.P.; Valmas, C.; Martinez, O.; Sanchez, F.M.; Basler, C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007, 81, 13469-13477.
33. Elliott, L.H.; Kiley, M.P.; McCormick, J.B. Descriptive analysis of Ebola virus proteins. Virology 1985, 147, 169-176.
34. Licata, J.M.; Johnson, R.F.; Han, Z.; Harty, R.N. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 2004, 78, 7344-7351.
35. Hoenen, T.; Groseth, A.; Kolesnikova, L.; Theriault, S.; Ebihara, H.; Hartlieb, B.; Bamberg, S.; Feldmann, H.; Stroher, U.; Becker, S. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J. Virol. 2006, 80, 7260-7264.
36. Hoenen, T.; Jung, S.; Herwig, A.; Groseth, A.; Becker, S. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 2010, 403, 56-66.
37. Huang, Y.; Xu, L.; Sun, Y.; Nabel, G.J. The assembly of Ebola virus nucleocapsid requires virionassociated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol. Cell 2002, 10, 307-316.
38. Noda, T.; Halfmann, P.; Sagara, H.; Kawaoka, Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J. Infect. Dis. 2007, 196, S247-S250.
39. Watanabe, S.; Noda, T.; Halfmann, P.; Jasenosky, L.; Kawaoka, Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J. Infect. Dis. 2007, 196, S284-290.
40. Bray, M.; Davis, K.; Geisbert, T.; Schmaljohn, C.; Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1999, 179, S248-258.
41. Ebihara, H.; Takada, A.; Kobasa, D.; Jones, S.; Neumann, G.; Theriault, S.; Bray, M.; Feldmann, H.; Kawaoka, Y. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006, 2, e73.
42. Volchkov, V.E.; Chepurnov, A.A.; Volchkova, V.A.; Ternovoj, V.A.; Klenk, H.D. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000, 277, 147-155.
43. Mateo, M.; Reid, S.P.; Leung, L.W.; Basler, C.F.; Volchkov, V.E. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 2010, 84, 1169-1175.
44. Reid, S.P.; Leung, L.W.; Hartman, A.L.; Martinez, O.; Shaw, M.L.; Carbonnelle, C.; Volchkov, V.E.; Nichol, S.T.; Basler, C.F. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80, 5156-5167.
45. Cros, J.F.; Garcia-Sastre, A.; Palese, P. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 2005, 6, 205-213.
46. O'Neill, R.E.; Palese, P. NPI-1, the human homolog of SRP-1, interacts with influenza virus nucleoprotein. Virology 1995, 206, 116-125.
47. Fontes, M.R.; Teh, T.; Jans, D.; Brinkworth, R.I.; Kobe, B. Structural basis for the specificity of bipartite nuclear localization sequence binding by importin-alpha. J. Biol. Chem. 2003, 278, 27981-27987.
48. Lee, M.S.; Lebeda, F.J.; Olson, M.A. Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly. J. Struct. Biol. 2009, 167, 136-144.
49. Enterlein, S.; Schmidt, K.M.; Schumann, M.; Conrad, D.; Krahling, V.; Olejnik, J.; Muhlberger, E. The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus. J. Virol. 2009, 83, 4508-4519.
50. Valmas, C.; Grosch, M.N.; Schumann, M.; Olejnik, J.; Martinez, O.; Best, S.M.; Krahling, V.; Basler, C.F.; Muhlberger, E. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010, 6, e1000721.
51. Dessen, A.; Volchkov, V.; Dolnik, O.; Klenk, H.D.; Weissenhorn, W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J. 2000, 19, 4228-4236.
52. Gomis-Ruth, F.X.; Dessen, A.; Timmins, J.; Bracher, A.; Kolesnikowa, L.; Becker, S.; Klenk, H.D.; Weissenhorn, W. The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure 2003, 11, 423-433.
53. Ruigrok, R.W.; Schoehn, G.; Dessen, A.; Forest, E.; Volchkov, V.; Dolnik, O.; Klenk, H.D.; Weissenhorn, W. Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. J. Mol. Biol. 2000, 300, 103-112.